945652-35-7

Basic information

• Product Name: tert-butyl 2-hydroxycyclopentylcarbamate
• Synonyms: tert-butyl 2-hydroxycyclopentylcarbamate
• CAS NO: 945652-35-7
• Molecular Formula: C₁₀H₁₉NO₃
• Molecular Weight: 201.26276
• Mol File: 945652-35-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: tert-butyl 2-hydroxycyclopentylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-hydroxycyclopentylcarbamate(945652-35-7)
• EPA Substance Registry System: tert-butyl 2-hydroxycyclopentylcarbamate(945652-35-7)

Safety Data

• Hazardous Substances Data: 945652-35-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Tert-butyl 2-hydroxycyclopentylcarbamate is utilized as a protecting group in the synthesis of pharmaceuticals. Its application is crucial for protecting specific functional groups during the chemical reactions involved in drug production, ensuring the desired product is obtained without unwanted side reactions.
Used in Organic Synthesis:
In the broader field of organic synthesis, tert-butyl 2-hydroxycyclopentylcarbamate serves as a protecting agent for functional groups. This role is vital for the successful synthesis of complex organic compounds, where the protection of certain groups can prevent interference with other parts of the molecule during the reaction process.
Used in Chemical Research:
Tert-butyl 2-hydroxycyclopentylcarbamate is also employed in chemical research for the study and development of new synthetic pathways and methodologies. Its use as a protecting group can facilitate the exploration of novel reactions and the synthesis of new compounds with potential applications in various industries.

Upstream product

• 285-67-6 Cyclopentene oxide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 89381-13-5 trans-2-hydroxycyclopentylamine 

Downstream Products

• 1193388-07-6 tert-butyl N-(2-aminocyclopentyl)carbamate 

Relevant articles and documents

2-QUINOLONE DERIVED INHIBITORS OF BCL6

The present invention relates to compounds of formula I that function as inhibitors of BCL6(B- cell lymphoma 6) activity: Formula I wherein X1, X2, X3, R1, R2, R3, R4 and R5 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer,as well as other diseases or conditions in which BCL6 activity is implicated.

CARBOXAMIDE INHIBITORS OF IRAK4 ACTIVITY

The present invention relates to carboxamide inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

Purine derivatives

A compound of formula (I), or a pharmaceutically acceptable salt thereof: STR1 wherein X is hydrogen, amino, halogen, hydroxy, lower alkoxy or lower alkyl andR 1 is STR2 wherein Y is methylene or a valence bond, R 2 and R 5 is H or lower, straight or branched alkyl,R 3 is H or lower alkyl, orR 2 and R 3 can together form a cyclobutyl, cyclopentyl, cyclohexyl or phenyl ring,Z is oxygen, methylene, sulphur, sulphonyl or a valence bond,R 4 is H, lower alkyl, aralkyl, a mono or bicyclic aromatic system optionally substituted with various groups.The compounds have been found useful for treating central nervous system ailments.

2, N6 -disubstituted adenosines, tri-O-ester derivatives and their pharmaceutical compositions to treat ischemias

A compound of formula (I), or a pharmaceutically acceptable salt thereof: STR1 wherein X is halogen, trifluoromethyl, cyano, C 1-6 -alkoxy, C 1-6 -alkylthio, C 1-6 -alkylamino or C 1-6 -dialkylamino;R 1 and R 4 are H or straight or branched C 1-6 -alkyl o